These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22575065)

  • 1. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit.
    Verhoeven F; Bossert M; Lohse-Walliser A; Balblanc JC
    Joint Bone Spine; 2012 Oct; 79(5):524-6. PubMed ID: 22575065
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 3. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 4. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
    Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
    Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
    Barthel HR
    Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
    [No Abstract]   [Full Text] [Related]  

  • 8. Crohn's disease unmasked following etanercept treatment for ankylosing spondylitis.
    Jethwa H; Mann S
    BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23813506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulomatous disease in a child treated with etanercept.
    Alhajri M; Aljumaah S; Aleyouni Y; Al-Qahtani F; Alhazzaa S; Al-Mayouf SM
    Int J Rheum Dis; 2013 Aug; 16(4):472-4. PubMed ID: 23826822
    [No Abstract]   [Full Text] [Related]  

  • 10. Demyelination during anti-TNFα therapy for ankylosing spondylitis.
    Mercieca C; Vella N; Borg AA
    Mod Rheumatol; 2012 Apr; 22(2):303-7. PubMed ID: 21748364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept-associated right abducens nerve palsy in rheumatoid arthritis.
    Lai CC; Hsiao KH; Chang YS; Tsai CY; Chou CT
    Int J Rheum Dis; 2012 Oct; 15(5):e117-9. PubMed ID: 23083045
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of sarcoidosis following etanercept treatment: a report of three cases.
    Skoie IM; Wildhagen K; Omdal R
    Rheumatol Int; 2012 Apr; 32(4):1049-53. PubMed ID: 20062997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
    Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
    Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of etanercept in ankylosing spondylitis hip lesions.
    Wang D; Ma L; Wu D
    Joint Bone Spine; 2011 Oct; 78(5):531-2. PubMed ID: 21570332
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.